戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he presence of the pharmacological chaperone astemizole.
2    Treatment of hindlimb-suspended mice with astemizole, a known Merg1a channel blocker, inhibits atr
3 ive histamine1 (H1) receptor antagonist drug astemizole, a widely prescribed antihistamine.
4 imilar findings were obtained with the drugs astemizole and cisapride, as well as with high concentra
5 tro ATPase assays confirmed three (ebastine, astemizole and clotrimazole) out of seven tested candida
6                 In head-to-head comparisons, astemizole and ipratropium were outperformed by several
7  drugs approved for human use and identified astemizole and tacrolimus, which reduced cell-surface Pr
8                           The metabolites of astemizole and those of other antihistamine compounds ha
9 hemistry optimization of an ester-containing astemizole (AST) analogue 1 with an associated metabolic
10 ethylastemizole, the principal metabolite of astemizole, blocks delayed rectifier potassium (K+) chan
11                                              Astemizole, but not tacrolimus, prolonged the survival t
12 Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and ot
13  phenotype cells and was inactive in a [(3)H]astemizole competitive binding assay for hERG liability
14  a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine
15 exposure of NRVMs to LUF7244 or LUF7244 plus astemizole did not affect their viability, excitability,
16              We tested in silico five drugs (astemizole, dofetilide, ibutilide, bepridil, and diltiaz
17 mperature for R752W or with the hERG blocker astemizole for G601S dissociates channel-chaperone compl
18 ts and the favorable drug characteristics of astemizole, including its ability to cross the blood-bra
19 n and torsade de pointes are associated with astemizole intake and have been ascribed to block the re
20 olongation and torsade de pointes found with astemizole intake may principally be caused by the proar
21                                              Astemizole is used in humans to treat seasonal allergic
22 nt with undetectable serum concentrations of astemizole (< 0.5 ng/ml) and "therapeutic" concentration
23               Desmethylastemizole, the major astemizole metabolite, blocks the repolarizing K+ curren
24 t ventricular myocyte (NRVM) monolayers with astemizole or sertindole caused heterogeneous prolongati
25 e, exposure to the pharmacological chaperone astemizole, or specific mutations in the selectivity fil
26 pine, (RR = 2.03, 95% C.I. = 1.22-3.38), and astemizole, (RR = 1.70, 95% C.I. = 1.28-2.26) outperform
27 inities of typical blockers (ie, dofetilide, astemizole, sertindole, and cisapride) were significantl
28                                              Astemizole stimulated autophagy, a hitherto unreported m
29                                              Astemizole undergoes extensive first-pass metabolism, an